Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avatrombopag for thrombocytopenia in hepatocellular carcinoma patients receiving immunotherapy/targeted/antiangiogenic therapy
ChiCTR2200065912Phase 4Recruiting
- Sponsor
- Fuyang Second People's Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avatrombopag in Thrombocytopenia, sponsored by Fuyang Second People's Hospital. Primary endpoint: Platelet count. Started Dec 2022; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2200065912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065912.